

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of claims:

1. (cancelled)
2. (cancelled)
3. (currently amended) The pharmaceutical product of claim 25 [[1]], wherein said pharmaceutical is a psychotropic.
4. (currently amended) The pharmaceutical product of claim 3, wherein said psychotropic is an [[a]] anti-anxiety therapeutic.
5. (previously presented) The pharmaceutical product of claim 3, wherein said psychotropic is an insomnia therapeutic.
6. (previously presented) The pharmaceutical product of claim 3, wherein said psychotropic is an antidepressant.

7. (previously presented) The pharmaceutical product of claim 6, wherein said antidepressant is selected from the group consisting of Fluoxetine HCl, Paroxetine HCl, Sertraline HCl, [[and]] Venlafaxine HCl, Amitriptyline, Nortriptyline, Imipramine, Desipramine, Doxepin, Trimipramine, Clomipramine, Protriptyline, Amoxapine, Maprotiline, Phenelzine, Tranylcypromine, Fluvoxamine, Venlafaxine, Trazodone, Nefazodone, Mirtazapine, Bupropion, and [[or]] mixtures thereof.

8. (currently amended) The pharmaceutical ~~encapsulated~~ product of claim 7, wherein said antidepressant ~~pharmaceutical~~ is Fluoxetine HCl.

9. (currently amended) The pharmaceutical ~~encapsulated~~ product of claim 25 [[1]], wherein said pharmaceutical is a gastrointestinal therapeutic.

10. (currently amended) The pharmaceutical ~~encapsulated~~ product of claim 9, wherein said gastrointestinal therapeutic is an [[a]] ulcer therapeutic.

11. (currently amended) The pharmaceutical ~~encapsulated~~ product of claim 10, wherein said ulcer

therapeutic is selected from the group consisting of Omeprazole, Lansoprazole, Ranitidine HCl, Famotidine, Nizatidine, Teprenone, Cimetidine, Rabeprazole sodium, Sulpiride, and ~~[[or]]~~ mixtures thereof.

12. (currently amended) The pharmaceutical ~~encapsulated~~ product of claim 11, wherein said ulcer therapeutic is Omeprazole.

13. (currently amended) The pharmaceutical ~~encapsulated~~ product of claim 9, wherein said gastrointestinal therapeutic is an ~~[[a]]~~ anti-emetic.

14. (currently amended) The pharmaceutical ~~encapsulated~~ product of claim 13, wherein said anti-emetic is selected from the group consisting of Ondansetron HCl, Granisetron HCl, dimenhydrinate, Tropisetron, Dolasetron mesylate, Cisapride, Sulfasalazine, Balsalazide, Infliximab, and ~~[[or]]~~ mixtures thereof.

15. (currently amended) The pharmaceutical ~~encapsulated~~ product of claim 14, wherein said anti-emetic is dimenhydrinate.

16. (currently amended) The pharmaceutical
~~encapsulated~~ product of claim 9, wherein said
gastrointestinal therapeutic is an ~~[[a]]~~ anti-diarrheal
therapeutic.

17. (currently amended) The pharmaceutical
~~encapsulated~~ product of claim 16, wherein said anti-
diarrheal therapeutic is selected from the group consisting
of Loperamide HCl, diphenoxylate, codeine phosphate,
camphorated opium tincture, and ~~[[or]]~~ mixtures thereof.

18. (currently amended) The pharmaceutical
~~encapsulated~~ product of claim 17, wherein said anti-
diarrheal therapeutic is Loperamide HCl.

19. (currently amended) The pharmaceutical
~~encapsulated~~ product of claim 25 ~~[[1]]~~, wherein said
pharmaceutical is a migraine therapeutic.

20. (currently amended) The pharmaceutical
~~encapsulated~~ product of claim 19, wherein said migraine
therapeutic is selected from the group consisting of
sumatriptan succinate, amitriptyline, methysergide,
propranolol, valproate, verapamil, dihydroergotamine,

ergotamine, metoclopramide, naratriptan, prochlorperazine, rizatriptan benzoate, zolmitriptan, eletriptan, acetaminophen, aspirin, NSAID's, opioids, and [[or]] mixtures thereof.

21. (currently amended) The pharmaceutical ~~encapsulated~~ product of claim 20, wherein said migraine therapeutic is sumatriptan succinate.

22. (currently amended) The pharmaceutical ~~encapsulated~~ product of claim 25 ~~[[1]]~~, wherein said pharmaceutical is a therapeutic for the treatment of hypertension.

23. (currently amended) The pharmaceutical ~~encapsulated~~ product of claim 22, wherein said therapeutic is selected from the group consisting of nifedipine, amlodipine besylate, losartan potassium, lisinopril, felodipine, benazepril HCl, ramipril, irbesartan, verapamil HCl, bisoprolol fumarate and hydrochlorothiazide, amlodipine and benazepril HCl, clonidine, candesartan, cilexetil, diltiazem, nicardipine, imidapril,trandolapril, eprosartan mesylate, nilvadipine, ~~verapamil HCl~~, temocapril, prazosin HCl, isradipine, cilazapril, celiprolol,

bisoprolol, betazolol HCl, ramipril, nisoldipine,
lisinopril, trandolapril, and nisoldipine.

24. (currently amended) The pharmaceutical
~~encapsulated~~ product of claim 23, wherein said therapeutic
is nifedipine.

25. (new) A pharmaceutical product, comprising:

- a) a therapeutically-effective amount of a
pharmaceutical;
- b) at least one compressible material; and
- c) at least one lubricating material;

wherein said product is in the form of a caplet having
a diameter from about 1 millimeter to about 3 millimeters
and a length from about 1 millimeter to about 7 millimeters.

26. (new) The pharmaceutical product of Claim 25,
wherein said product is in the form of a caplet having a
diameter from about 1 millimeter to about 3 millimeters and
a length from about 1 millimeter to about 3 millimeters.

27. (new) The pharmaceutical product of Claim 25,
wherein said at least one lubricating material is present in
an amount of up to about 5% by weight of the product.